Structural insights on the role of antibodies in HIV-1 vaccine and therapy - Test2 - elhamkhani - TriplyDB

Structural insights on the role of antibodies in HIV-1 vaccine and therapy

Structural insights on the role of antibodies in HIV-1 vaccine and therapy

http://www.wikidata.org/entity/Q26829461

about

How Follicular Dendritic Cells Shape the B-Cell Antigenome HIV-Host Interactions: Implications for Vaccine Design Antibody responses to envelope glycoproteins in HIV-1 infection Forward Vaccinology: CTL Targeting Based upon Physical Detection of HLA-Bound Peptides Virological features associated with the development of broadly neutralizing antibodies to HIV-1 Structural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors Deconstructing the Antiviral Neutralizing-Antibody Response: Implications for Vaccine Development and Immunity Structural basis for the inhibition of HIV-1 Nef by a high-affinity binding single-domain antibody Antiviral Therapy by HIV-1 Broadly Neutralizing and Inhibitory Antibodies Recent Progress toward Engineering HIV-1-Specific Neutralizing Monoclonal Antibodies Perspectives for immunotherapy: which applications might achieve an HIV functional cure?Bottlenecks in HIV-1 transmission: insights from the study of founder viruses HIV-1 gp120 as a therapeutic target: navigating a moving labyrinth Protein Crystallography in Vaccine Research and Development Willingness to participate in HIV therapeutic vaccine trials among HIV-infected patients on ART in China Cross-Neutralizing Antibodies in HIV-1 Individuals Infected by Subtypes B, F1, C or the B/Bbr Variant in Relation to the Genetics and Biochemical Characteristics of the env Gene HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers Structure of 2G12 Fab2 in complex with soluble and fully glycosylated HIV-1 Env by negative-stain single-particle electron microscopy Humanized Immunoglobulin Mice: Models for HIV Vaccine Testing and Studying the Broadly Neutralizing Antibody Problem.Asymmetric recognition of HIV-1 Envelope trimer by V1V2 loop-targeting antibodies.Highlights from the 2014 International Symposium on HIV & Emerging Infectious Diseases (ISHEID): from cART management to the end of the HIV pandemic.Mutations in HIV-1 envelope that enhance entry with the macaque CD4 receptor alter antibody recognition by disrupting quaternary interactions within the trimer.Generation of Long-Lived Bone Marrow Plasma Cells Secreting Antibodies Specific for the HIV-1 gp41 Membrane-Proximal External Region in the Absence of Polyreactivity.A non-canonical binding interface in the crystal structure of HIV-1 gp120 core in complex with CD4 Broad and potent cross clade neutralizing antibodies with multiple specificities in the plasma of HIV-1 subtype C infected individuals.Which Antibody Functions are Important for an HIV Vaccine?Antibody 10-1074 suppresses viremia in HIV-1-infected individuals Coexistence of potent HIV-1 broadly neutralizing antibodies and antibody-sensitive viruses in a viremic controller A human inferred germline antibody binds to an immunodominant epitope and neutralizes Zika virus.Why HIV virions have low numbers of envelope spikes: implications for vaccine development.Chemically modified peptides based on the membrane-proximal external region of the HIV-1 envelope induce high-titer, epitope-specific nonneutralizing antibodies in rabbits Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice.Insights into vaccine development for acquired immune deficiency syndrome from crystal structures of human immunodeficiency virus-1 gp41 and equine infectious anemia virus gp45.HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1.Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo High frequencies of polyfunctional CD8+ NK cells in chronic HIV-1 infection are associated with slower disease progression Advances in HIV prevention for serodiscordant couples.Two classes of broadly neutralizing antibodies within a single lineage directed to the high-mannose patch of HIV envelope Vaccine-induced plasmablast responses in rhesus macaques: phenotypic characterization and a source for generating antigen-specific monoclonal antibodies.Class-switched memory B cells remodel BCRs within secondary germinal centers.

P2860

Q26742173-12A19EEB-9C16-4A53-907F-0C5F1F892321 Q26765966-8BDB3B5F-B44C-4A12-B469-166914A46D2F Q26991572-4A4E529C-6993-4658-A998-1608843A20E9 Q27008977-E793ADCF-30F2-473D-B5C0-21C582F79AA2 Q27025177-CC8BFBB8-7864-45A0-A2A6-3832656264D6 Q27643993-A4D09AD8-5291-4E44-8557-81673E11BCB0 Q27654848-8F135571-4B98-4446-9EE1-9025D9A17D5E Q27682132-ADAA2923-920A-41DF-99E8-D1ADAE2ECD04 Q28066335-6A54C2F6-EB8B-4DFC-B1F8-61E2C7D46F74 Q28068946-49543B83-0412-4DA0-948A-592E04BFCD97 Q28078726-B04E1528-3623-4CDD-BA34-1A8127FF160D Q28082862-361B73C4-B19D-46AD-B443-CB2FE4D0407B Q28086826-4D5CD601-A3BB-4A5C-969A-2502D84377C5 Q28087528-35399122-7DB6-4923-9D5F-CCFABA289D9B Q28544731-34EF1E30-628E-478E-BD77-9463B6270652 Q28554907-F49089B7-3D0E-4259-909D-593F0BB7C2B7 Q28647225-7978B0D7-311F-4364-9D2B-8973922D1670 Q28654490-F36BC516-55F8-478A-B587-276AEE13D380 Q30234773-B06A6245-5DAE-4BCD-89A3-152F9F90FC51 Q30352300-1F33D140-29A6-40D5-AD5B-C42C12D0A4C3 Q30366175-4B6903C0-450C-4124-B601-2CF9E2A5CCA1 Q30368471-A22B5326-2761-4F98-AF39-AC56EAA89299 Q30391094-0525CA41-FC08-42A8-A2FF-7B53FF146F52 Q33587774-DEB95F86-1C15-4DB3-A36A-AC511AEF0775 Q33594304-7E3B9367-4302-4D41-B24C-2E98CF0497F3 Q33772637-1ADB5498-9C81-4AC8-A530-314BFA1D73B0 Q33786443-663975FA-0808-482F-B1A2-0FD862F377A5 Q33786447-475682D5-C6CE-4327-B95F-499147A109E1 Q33825684-76119833-52EE-42B6-BFD0-718D7BB1D452 Q34016070-08D0C7AA-FF9D-4874-BC03-1B5D626D5ED7 Q34057672-A012A3A5-0858-413F-812A-DDDDE43B1CD5 Q34180174-4E69F7F8-72E6-402D-BA26-A6900BD8EA93 Q34485027-B3852670-94F2-4EDC-B995-396670707788 Q34527469-303A66D9-2CB7-43CB-AB07-05BD36039A33 Q34527478-A9A9E4BA-AB08-4084-AF94-359F4FC66462 Q34593740-68AC535A-71C8-4280-BD48-CCD8F24EC14E Q34714168-525F7A9A-54D8-45AA-800E-1DADFFE4390D Q34991017-3708CD0A-8AEB-4C5B-AEF0-647BC7FAE0DA Q35071821-C034A665-4D69-4043-B7FB-EC799785A029 Q35097102-B37F5A7F-1091-4CE9-A31E-79FB789EF12A

P2860

Structural insights on the role of antibodies in HIV-1 vaccine and therapy

http://www.wikidata.org/entity/Q26829461

description

2014 nî lūn-bûn

@nan

2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Structural insights on the role of antibodies in HIV-1 vaccine and therapy

@ast

Structural insights on the role of antibodies in HIV-1 vaccine and therapy

@en

Structural insights on the role of antibodies in HIV-1 vaccine and therapy

@nl

type

label

Structural insights on the role of antibodies in HIV-1 vaccine and therapy

@ast

Structural insights on the role of antibodies in HIV-1 vaccine and therapy

@en

Structural insights on the role of antibodies in HIV-1 vaccine and therapy

@nl

prefLabel

Structural insights on the role of antibodies in HIV-1 vaccine and therapy

@ast

Structural insights on the role of antibodies in HIV-1 vaccine and therapy

@en

Structural insights on the role of antibodies in HIV-1 vaccine and therapy

@nl

P1433

Q26829461-BD5D8988-D9E6-44C0-8717-4F69599C4C96

P1476

Q26829461-B81FD50A-175A-45F4-86B2-0FC9FCF5A95D

P2093

Q26829461-0E7B0325-2043-44DA-B5CB-27366E65A7D7

Q26829461-6B1854C7-FD98-4A38-99F2-861957DA5E37

Q26829461-72E0B09A-D45E-4DDF-A41A-163930DFD2BF

Q26829461-7A895AB7-E943-4412-984E-91B38B0E1DED

Q26829461-EC7A72E9-4BA6-4AEF-A338-56EF220BF51A

Q26829461-F2608B0C-844B-4EAC-81ED-CB84BE880D96

P2860

Q26829461-00A883BE-0749-4A37-9B53-C689CCCC98A1

Q26829461-00DDDEEB-4F7E-4E23-BAEF-6BCB744C957B

Q26829461-02093F02-5FEF-450A-87D4-89C063CD1A64

Q26829461-053A2B18-457C-4986-ABB3-234C93E6E131

Q26829461-06D0AD40-6E4E-4AE2-B076-6FDC085BA2D1

Q26829461-071E1117-8410-41D0-A6AE-0113C7845960

Q26829461-08FB1436-58F7-44B0-B018-6E87A1D96F51

Q26829461-094C33A6-6D5A-45D5-BB2D-B96553466D8B

Q26829461-09EC9F57-3E81-46EC-A090-4D28C8CAC0FE

Q26829461-0A565259-BA66-45F2-A620-E2E63BE27E46

P304

Q26829461-857F4295-1557-4B7D-82DA-899CDA291935

P31

Q26829461-AE6CD2D5-E7BF-4F03-BEBE-592CB8222C27

P3181

Q26829461-C2685EA8-8F03-4590-90BB-D18F93E1933C

P356

Q26829461-6B82E801-C776-4FEA-B30E-CCCE0AE93B85

P407

Q26829461-0EDDDAD3-1E65-4385-B3F1-BE9C7FF55DFE

P433

Q26829461-2A5F37DF-0730-484D-82AF-94AE831DAD01

P478

Q26829461-C81FD34C-9C83-416A-8B98-5C66FFAFC5D0

P577

Q26829461-188515F0-5654-4085-8033-DD920529AE14

P5875

Q26829461-54904514-28FE-4B78-8CEF-7EAC2C70FE27

P698

Q26829461-23BA6EDF-C689-4BA4-86EA-7B9BEDE9E237

P921

Q26829461-64C3234E-3DC7-4638-9BB7-76A3040BBAAA

P932

Q26829461-E2BCAB29-848C-4DEF-86CC-E65BF31C6219

P3181

P356

J.CELL.2014.01.052

P1433

P1476

Structural insights on the role of antibodies in HIV-1 vaccine and therapy

@en

P2093

Anthony P. West

http://www.w3.org/2001/XMLSchema#string

Florian Klein

http://www.w3.org/2001/XMLSchema#string

Johannes F. Scheid

http://www.w3.org/2001/XMLSchema#string

Louise Scharf

http://www.w3.org/2001/XMLSchema#string

Michel C. Nussenzweig

http://www.w3.org/2001/XMLSchema#string

Pamela J. Bjorkman

http://www.w3.org/2001/XMLSchema#string

P2860

HIV-1 superinfection in women broadens and strengthens the neutralizing antibody response

Few and far between: how HIV may be evading antibody avidity

Increasing the potency and breadth of an HIV antibody by using structure-based rational design

Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome

HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors

A Blueprint for HIV Vaccine Discovery

Antibodies in HIV-1 vaccine development and therapy

An anti-HIV-1 V3 loop antibody fully protects cross-clade and elicits T-cell immunity in macaques mucosally challenged with an R5 clade C SHIV

A fusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodies

Antibody domain exchange is an immunological solution to carbohydrate cluster recognition

P304

633-48

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

244703

http://www.w3.org/2001/XMLSchema#string

P356

10.1016/J.CELL.2014.01.052

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

156

http://www.w3.org/2001/XMLSchema#string

P577

2014-02-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260217648

http://www.w3.org/2001/XMLSchema#string

P698

24529371

http://www.w3.org/2001/XMLSchema#string

P921

P932

4041625

http://www.w3.org/2001/XMLSchema#string